Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy

Next Previous
X
Search
Trial Profile

Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Antineoplastics; Capecitabine; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms Lux-Breast 3
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 16 Nov 2015 Results published in the Lancet Oncology
    • 07 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 05 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top